Compare COE & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | DERM |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.1M | 135.3M |
| IPO Year | 2015 | 2021 |
| Metric | COE | DERM |
|---|---|---|
| Price | $22.81 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 7.6K | ★ 311.9K |
| Earning Date | 03-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $47.42 |
| Revenue Next Year | N/A | $55.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $13.60 | $4.31 |
| 52 Week High | $56.13 | $9.56 |
| Indicator | COE | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 33.64 |
| Support Level | $15.32 | $4.31 |
| Resistance Level | $29.46 | $7.92 |
| Average True Range (ATR) | 1.92 | 0.44 |
| MACD | 0.63 | -0.06 |
| Stochastic Oscillator | 81.67 | 28.28 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.